Stock Price
109.10
Daily Change
-6.52 -5.64%
Monthly
-23.59%
Yearly
60.16%
Q2 Forecast
99.25

Insmed reported $361.01M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
DBV Technologies USD 58.02M 8.54M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026